PDL BioPharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PDL BioPharma, Inc.
Fresenius Kabi has reported positive Phase I data for its MSB11456 proposed tocilizumab biosimilar rival to Actemra/Ro-Actemra, against the backdrop of shortages for the brand which is being used in some regions to treat COVID-19.
The approval of China's second CAR-T therapy has come amid reimbursement challenges, despite the pricing of its direct competitor being much lower than in the US. Chinese developers are pinning their hopes on rapid domestic market expansion via commercial insurance tie-ups as other CAR-Ts move through local development.
Biotech is determining which of its mid-stage FXR candidates – MET409 and MET642 – will offer the best overall profile to take into Phase IIb. It is also studying ‘409 in combination with Jardiance and will test the FXR class in inflammatory bowel disease.
Appeals court finds that Juno/BMS patent is invalid, overturning $1.2bn jury verdict against Kite/Gilead. Ruling illustrates court does not like functionally-defined patent claims, attorneys say. Decision could impact future CAR-T patents and disputes.
- Large Molecule
- Other Names / Subsidiaries
- Eos Biotechnology, Inc.
- LENSAR, Inc.
- Noden Pharma DAC
- Noden USA
- Protein Design Labs, Inc.